Chronic incretin-based therapy in cystic fibrosis-related diabetes: A tale of 3 patients treated with sitagliptin for over 5 years
- 2 March 2021
- journal article
- research article
- Published by Elsevier BV in Journal of Cystic Fibrosis
- Vol. 20 (6), e124-e128
- https://doi.org/10.1016/j.jcf.2021.02.005
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Hypoglycemia in cystic fibrosis: Prevalence, impact and treatmentJournal of Cystic Fibrosis, 2019
- Cystic fibrosis related diabetes: Medical managementJournal of Cystic Fibrosis, 2019
- Cystic Fibrosis–Related Diabetes: Pathophysiology and Therapeutic ChallengesClinical Medicine Insights: Endocrinology and Diabetes, 2019
- Use of Dipeptidyl Peptidase-4 Inhibitors in a Subset of Patients with Cystic Fibrosis Related DiabetesJournal of Diabetes & Metabolism, 2015
- Reduced levels of active GLP-1 in patients with cystic fibrosis with and without diabetes mellitusJournal of Cystic Fibrosis, 2012
- Clinical Care Guidelines for Cystic Fibrosis–Related DiabetesDiabetes Care, 2010
- Cystic Fibrosis–Related Diabetes: Current Trends in Prevalence, Incidence, and MortalityDiabetes Care, 2009
- The changing face of the exocrine pancreas in cystic fibrosis: the correlation between pancreatic status, pancreatitis and cystic fibrosis genotypeEuropean Journal of Gastroenterology & Hepatology, 2008